251115 Preparing for a tsunami of resistant infections: What FDA data tell us about the importance of industrial meat production

Monday, October 31, 2011: 4:30 PM

David Wallinga, MD, MPA , Food and Health Program, Institute for Agriculture & Trade Policy, Minneapolis, DC
New evidence is overturning the conventional wisdom that antibiotic resistance is necessarily a function of antibiotic use in humans. Contributing to that sea change are three things: Basic microbiological understanding that resistace is a systems or ecological phenomenon; new FDA data confirming that more than 70% of all U.S. antimicrobials are used not in clinical settings, but on farms; and the emergence of new, resistant pathogenic strains on food and in the farm environment of particular concern to public health. This presenttation discusses the first two topics, providing a brief overview of how to think ecologically or in systems about ecological resistance, and also looking in depth at the FDA data, publicly released in December 2010.

Learning Areas:
Protection of the public in relation to communicable diseases including prevention or control
Public health or related nursing
Public health or related public policy
Public health or related research
Systems thinking models (conceptual and theoretical models), applications related to public health

Learning Objectives:
1) List 2-3 items of public health significance from recent FDA data on the prevalence of antimicrobial use in food animals. 2) Give 3 federal agencies in which leadership has recently linked antimicrobial use in food animals to a significant public health threat.

Keywords: Food Safety, Antibiotic Resistance

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am a physician and have worked in this area for 10 years or more.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.